Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The RSUs cover 55,867 shares and were granted to 59 recently hired non-executive employees as an inducement for joining the company.
- Several technology and biopharmaceutical companies, including MicroVision, GRAIL, Spero Therapeutics, and Apnimed, announced equity inducement grants this week to attract new talent.
- These grants operate under Nasdaq Listing Rule 5635, which allows companies to issue equity as a material inducement to individuals entering employment.
- On Wednesday, MicroVision granted 674,536 restricted stock units to Chief Commercial Officer James Byun and 562,114 to Chief Financial Officer Christine Chambers.
- Spero Therapeutics approved 102,000 restricted stock units and 67,600 stock options on Tuesday, while Apnimed granted options to 10 new non-executive employees on Monday.
- GRAIL recently awarded restricted stock units underlying 55,867 shares to 59 new employees, with these equity awards typically vesting over a four-year period.
14 Articles
14 Articles
MicroVision Announces Inducement Grants Pursuant to Nasdaq Listing Rule 5635(c)(4)
REDMOND, WA / ACCESS Newswire / September 4, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications, today announced that on September 2, 2026, it granted 674,536 restricted stock units…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the…
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common…
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
